Features	Training cohort	Validation cohort	P-value
Total	56	33	
Gender			0.5571
Male	42 (75%)	23 (69.7%)	
Female	14(25%)	10(30.3%)	
Age			0.4133
>=60	16(28.57%)	13(39.39%)	
<60	40(71.43%)	20(60.61%)	
Tumor entity			0.8186
HNSCC	24(42.86%)	16(48.49%)	
NSCLC	26(46.42%)	13(39.39%)	
others	6(10.71%)	4(12.12%)	
Brain metastasis			0.6538
Yes	12(21.43%)	5(15.15%)	
No	44(78.57%)	28(84.85%)	
PD-L1 expression			0.8995
<1%	19(33.93%)	12(36.37%)	
1-49%	18(32.14%)	10(30.3%)	
50%-100%	17(30.36%)	11(33.33%)	
NA	2(3.57%)	0	

 Table 1. Baseline characteristics of metastatic cancer patients treated with ICI and for

 which immunophenotyping was performed before the second administration of ICI.